SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    de Guibert S, Jaccard A, Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica. 2006; 91: 425-426.
  • 2
    Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008; 112: 2687-2693.
  • 3
    Ghielmini M, Zucca E, Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009; 114: 1469-1476.
  • 4
    Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998; 16: 3803-3809.
  • 5
    LaCasce A, Vandergrift JL, Rodriguez MA, et al. R-CHOP, followed by high dose therapy and autologous stem cell rescue (HDT/ASCR), and R-HyperCVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell lymphoma: a comparative effectiveness analysis from the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 403.
  • 6
    Lefrere F, Delmer A, Levy V, et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica. 2004; 89: 1275-1276.
  • 7
    Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol. 2004; 15: 283-290.
  • 8
    Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23: 7013-7023; erratum 2006;24:724.
  • 9
    Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000; 39: 77-85.
  • 10
    van 't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R–CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009; 144: 524-530.
  • 11
    Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer. 2006; 107: 1014-1022.
  • 12
    Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010; 150: 200-208.
  • 13
    Feldman T, Mato AR, Zielonka T, et al. Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL) [abstract]. J Clin Oncol. 2010; 28( 15 suppl): 8067.
  • 14
    Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111: 558-565; erratum 2008;111:5761.
  • 15
    Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010; 115: 1530-1533.
  • 16
    Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood. 2008; 112: 2583; author reply 2583-2584.
  • 17
    Mato AR, Zielonka T, Feldman T, et al. The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC) [abstract]. J Clin Oncol. 2010; 28( 15 suppl): 8092.
  • 18
    Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25: 571-578.
  • 19
    de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 2001; 12: 29-37.
  • 20
    Gonzalez-Barca E, Canales M, Salar A, et al. Interim and end-of-treatment 18F-FDG-PET evaluation of patients with diffuse large B-cell lymphoma (DLBCL) treated with 6 cycles of dose-dense R-CHOP-14 immunochemotherapy plus pegfilgrastim for first-line treatment: an open-label clinical trial in Spain [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 3692.
  • 21
    Gonzalez-Barca E, Canales M, Vidal MJ, et al. Predictive value for event-free survival of interim 18F-FDG-PET in patients with diffuse large B-cell lymphoma (DLBCL) treated with 6 cycles of dose-dense R-CHOP-14 immunochemotherapy plus pegfilgrastim as first-line treatment: an open-label clinical trial In Spain [abstract]. Blood. (ASH Annual Meeting Abstracts) 2010; 116: 2793.
  • 22
    Hutchings M, Loft A, Hansen M, et al. FDG-PET after 2 cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107: 52-59.
  • 23
    Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000; 85: 613-618.
  • 24
    Kostakoglu L, Kostakoglu L. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas. Clin Lymphoma Myeloma. 2008; 8: 273-276.
  • 25
    Puccini B, Rigacci L, Pregno P, et al. Response assessment after induction therapy in diffuse large B cell lymphoma (DLBCL): role of fluorodeoxyglucose-positron emission tomography (FDG-PET) in comparison with computed tomography (CT) [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 4995.
  • 26
    Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001; 98: 2930-2934.
  • 27
    Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol. 2010; 28( 15_suppl): 8004.
  • 28
    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
  • 29
    Chong EA, Torigian DA, Alavi A, et al. Comparison of contrast-enhanced CT, PET/CT, PET, and low-dose non-contrast enhanced CT imaging of diffuse large B-cell, follicular, small lymphocytic/CLL, and marginal zone lymphomas [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 1402.
  • 30
    Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-positron emission tomography/computed tomography (PET) failed to predict different outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab-CHOP [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 99.
  • 31
    Sehn LH, Savage KJ, Hoskins P, et al. Limited-stage diffuse large B-cell lymphoma (DLBCL) patients with a negative PET scan following three cycles of R-CHOP can be effectively treated with abbreviated chemoimmunotherapy alone [abstract]. Blood. (ASH Annual Meeting Abstracts) 2007; 110: 787.
  • 32
    Trneny M, Bosly A, Bouabdallah K, et al. Independent predictive value of PET-CT pre transplant in relapsed and refractory patients with CD20 diffuse large B-cell lymphoma (DLBCL) included in the CORAL study [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 881.
  • 33
    Vitolo U, Chiappella A, Bello M, et al. The outcome of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-CHOP (R-CHOP) is not predicted by 18-FDG-positron emission tomography/computerized tomography (PET) performed at intermediate in-course evaluation, but only by PET assessed at the end of therapy [abstract]. Blood. (ASH Annual Meeting Abstracts) 2010; 116: 2819.
  • 34
    Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010; 37: 1633-1642.
  • 35
    Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma. 2008; 49: 1693-1701.
  • 36
    Gill S, Hicks RJ, Seymour JF, Gill S, Hicks RJ, Seymour JF. What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma? Leuk Lymphoma. 2008; 49: 1653-1656.
  • 37
    Gill S, Wolf M, Prince HM, et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008; 8: 159-165.
  • 38
    Karam M, Ata A, Irish K, et al. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl Med Commun. 2009; 30: 770-778.
  • 39
    Link BK. The mysteries of mantle cell lymphoma—do PET scans provide a clue? Leuk Lymphoma. 2008; 49: 1662-1663.
  • 40
    Schaffel R, Moskowitz CH, Maragulia JC, Portlock CS, Hedvat CV, Zelenetz AD. Prognostic significance of positron emission tomography (FDG-PET) at baseline and after 4 cycles of R-CHOP in 75 patients with mantle cell lymphoma treated with intensive chemotherapy and autologous stem cell rescue [abstract]. Blood. (ASH Annual Meeting Abstracts) 2009; 114: 1226.
  • 41
    Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of F-fluorodeoxyglucose positron emission tomography (F-FDG-PET) and a comparison of F-FDG-pet with gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007; 110: 652-659.